A Randomized, Double-Blind, Placebo-Controlled Trial of Desvenlafaxine Succinate in Adult Outpatients With Major Depressive Disorder
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: This study evaluated the efficacy and tolerability of desvenlafaxine succinate (desvenlafaxine) in the treatment of major depressive disorder (MDD). METHOD: In this 8-week, multicenter, randomized, double-blind, placebo-controlled trial, adult outpatients (aged 18-75 years) with a primary diagnosis of MDD (DSM-IV criteria) were randomly assigned to treatment with desvenlafaxine (100-200 mg/day) or placebo. The primary outcome measure was the 17-item Hamilton Rating Scale for Depression (HAM-D(17)) score at final on-therapy evaluation. The Clinical Global Impressions-Improvement scale (CGI-I) was the key secondary measure. Other secondary measures included the Montgomery-Asberg Depression Rating Scale (MADRS), Clinical Global Impressions-Severity of Illness scale, Visual Analog Scale-Pain Intensity (VAS-PI) overall and subcomponent scores, and HAM-D(17) response and remission rates. The study was conducted from June 2003 to May 2004. RESULTS: Of the 247 patients randomly assigned to treatment, 234 comprised the intent-to-treat population. Following titration, mean daily desvenlafaxine doses ranged from 179 to 195 mg/day. At endpoint, there were no significant differences in scores between the desvenlafaxine (N = 120) and placebo (N = 114) groups on the HAM-D(17) or CGI-I. However, the desvenlafaxine group had significantly greater improvement in MADRS scores (p = .047) and in VAS-PI overall pain (p = .008), back pain (p = .006), and arm, leg, or joint pain (p < .001) scores than the placebo group. The most common treatment-emergent adverse events (at least 10% and twice the rate of placebo) were nausea, dry mouth, constipation, anorexia, somnolence, and nervousness. CONCLUSION: Desvenlafaxine was generally safe and well tolerated. In this study, it did not show significantly greater efficacy than placebo on the primary or key secondary efficacy endpoints, but it did demonstrate efficacy on an alternate depression scale and pain measure associated with MDD. CLINICAL TRIALS REGISTRATION: ClinicalTrials.gov identifier NCT00063206.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An international study of the relation between somatic symptoms and depression
Simon, G. E., VonKorff, M., Piccinelli, M., Fullerton, C., & Ormel, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199910283411801 · Cited by 1,303 · cited 1×
“0 Gender, N (%) Female 74 (65) 67 (56) Male 40 (35) 53 (44) Ethnic origin, N (%) Asian 1 (< 1) 4 (3) Black 14 (12) 9 (8) Hispanic 14 (12) 11 (9) Native American 0 1 (< 1) White 85 (75) 95 (79) Height, cm Mean 167.”
The Economic Burden of Depression in the United States: How Did It Change Between 1990 and 2000?
Greenberg, P. E., Kessler, R. C., Birnbaum, H. G., Leong, S. A., Lowe, S. W., Berglund, P. A., & Corey-Lisle, P. K. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n1211 · Cited by 1,280 · cited 3×
“9 Current episode duration groups, N (%) < 6 mo 42 (37) 27 (23) 6 to < 12 mo 20 (18) 32 (27) 12 to < 24 mo 31 (27) 30 (25) 24 to < 60 mo 12 (11) 18 (15) 60 to < 120 mo 2 (2) 8 (7) ≥ 120 mo 7 (6) 5 (4) Baseline HAM-D17 total c Mean 23.”
The Association of Comorbid Depression With Mortality in Patients With Type 2 Diabetes
Katon, W. J., Rutter, C., Simon, G., Lin, E. H. B., Ludman, E., Ciechanowski, P., Kinder, L., Young, B., & Von Korff, M. (2005) · Diabetes Care · doi:10.2337/diacare.28.11.2668 · Cited by 640 · cited 1×
“Any adverse event 93 (79) 112 (93)** Body as a whole 57 (49) 66 (55) Abdominal pain 7 (6) 7 (6) Asthenia 8 (7) 13 (11) Back pain 7 (6) 4 (3) Flu syndrome 8 (7) 6 (5) Headache 36 (31) 37 (31) Infection 7 (6) 10 (8) Pain 9 (8) 7 (6) Digestive system 45 (38) 82 (68)*** Anorexia 2 (2) 16 (13)*** Constipation 7 (6) 20 (17)…”
Khan, A., Leventhal, R. M., Khan, S. R., & Brown, W. A. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200202000-00007 · Cited by 456
Internal and external validity of the WHO Well‐Being Scale in the elderly general population
Heun, R., Burkart, M., Maier, W., & Bech, P. (1999) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1999.tb00973.x · Cited by 160
Rudolph, R. L., & Feiger, A. D. (1999) · Journal of Affective Disorders · doi:10.1016/s0165-0327(99)00067-1 · Cited by 158 · cited 1×
“Any adverse event 93 (79) 112 (93)** Body as a whole 57 (49) 66 (55) Abdominal pain 7 (6) 7 (6) Asthenia 8 (7) 13 (11) Back pain 7 (6) 4 (3) Flu syndrome 8 (7) 6 (5) Headache 36 (31) 37 (31) Infection 7 (6) 10 (8) Pain 9 (8) 7 (6) Digestive system 45 (38) 82 (68)*** Anorexia 2 (2) 16 (13)*** Constipation 7 (6) 20 (17)…”
Cited by
Antidepressant Drug Effects and Depression Severity: A Patient-Level Meta-analysis
Fournier, J. C., DeRubeis, R. J., Hollon, S. D., Dimidjian, S., Amsterdam, J. D., Shelton, R. C., & Fawcett, J. (2010) · JAMA · doi:10.1001/jama.2009.1943 · Cited by 2,009
Undurraga, J., & Baldessarini, R. J. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.306 · Cited by 269
Carrozzino, D., Patierno, C., Fava, G. A., & Guidi, J. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000506879 · Cited by 263
Timmerby, N., Andersen, J. H., Søndergaard, S., Østergaard, S. D., & Bech, P. (2017) · Psychotherapy and Psychosomatics · doi:10.1159/000457131 · Cited by 134
Montgomery, S. A., Fava, M., Padmanabhan, S. K., J. Guico-Pabia, C., & Tourian, K. A. (2009) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32832fbb5a · Cited by 27
Metadata
- Authors
- Liebowitz, M. R., & Yeung, P. P.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2007-11-15
- Volume
- 68
- Issue
- 11
- Pages
- 1663-1672
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2144767826
- Cited by
- 72
- References
- 6
- FWCI
- 4.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Randomized, Double-Blind, Placebo-Controlled Trial of Desvenlafaxine Succinate in Adult Outpatients With Major Depressive Disorder. https://app.cochat.ai/papers/10.4088/jcp.v68n1105
- The paper
- Liebowitz, M. R., & Yeung, P. P. (2007). A Randomized, Double-Blind, Placebo-Controlled Trial of Desvenlafaxine Succinate in Adult Outpatients With Major Depressive Disorder. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.v68n1105
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.